An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease

ClinicalTrials.gov ID: NCT07764146

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07764146. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open Label Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of VY1706 in Participants With Early Alzheimer's Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

VY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study

Study identification

NCT ID: NCT07764146
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Voyager Therapeutics; Industry
Enrollment: 18 participants

Conditions and interventions

Conditions

Alzheimer s Disease

Interventions

VY1706 Low dose Drug
VY1706 Mid dose Drug
VY1706 High Dose Drug
Anti-AAV9 Total Antibody (TAb) Assay Device

Drug · Device

Eligibility (public fields only)

Age range: 30 Years to 80 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 3, 2026 (Actual)
Primary completion: Apr 28, 2029 (Estimated)
Completion: Apr 28, 2029 (Estimated)
Last update posted: Oct 29, 2026

2026 – 2029

United States locations

U.S. sites: 2
U.S. states: 1
U.S. cities: 2

Facility	City	State	ZIP	Site status
K2 Medical Research, LLC	Maitland	Florida	32751	Recruiting
AdventHealth Orlando	Orlando	Florida	32803	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07764146, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 29, 2026 · Synced Nov 15, 2026